Who are tetrastarch (Voluven)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HES 130/04, HES 130/0.4, Hydroxethyl starch.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tetrastarch-voluven.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

tetrastarch (Voluven) — Competitive Intelligence Brief

tetrastarch (Voluven) (tetrastarch (Voluven)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic colloid / Plasma volume expander. Area: Critical Care / Anesthesia.

marketed Synthetic colloid / Plasma volume expander Critical Care / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

tetrastarch (Voluven) (tetrastarch (Voluven)) — University of the Philippines. Tetrastarch is a synthetic colloid that expands intravascular volume by osmotically retaining fluid in the bloodstream.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
tetrastarch (Voluven) TARGET	tetrastarch (Voluven)	University of the Philippines	marketed	Synthetic colloid / Plasma volume expander
HES 130/04	HES 130/04	K. C. Rasmussen	marketed	Synthetic colloid / Plasma volume expander
HES 130/0.4	HES 130/0.4	University Hospital, Clermont-Ferrand	marketed	Synthetic colloid / Plasma volume expander
Hydroxethyl starch	Hydroxethyl starch	University Hospital, Clermont-Ferrand	phase 3	Synthetic colloid / Plasma volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic colloid / Plasma volume expander class)

University Hospital, Clermont-Ferrand · 2 drugs in this class
K. C. Rasmussen · 1 drug in this class
University of the Philippines · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tetrastarch (Voluven) — Competitive Intelligence Brief. https://druglandscape.com/ci/tetrastarch-voluven. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab